Medical Condition News

RSS

FDA approves St. Jude Medical's Trifecta valve for stented aortic valve replacement

St. Jude Medical, Inc., a global medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) approval for its Trifecta™ valve. The valve, a clinically-proven replacement for diseased, damaged or malfunctioning aortic heart valves, mimics the flow of a natural, healthy heart and represents a significant new product in the pericardial aortic stented tissue valve market.

21 Apr 2011

Brain trauma helped by nutrition

According to a report by the Institute of Medicine, military personnel who suffer traumatic brain injury need to be fed adequately and immediately to reduce the severity of trauma and improve their chance of survival. This finding has implications for people sustaining head injuries in other situations, such as sports and traffic accidents.

20 Apr 2011

InfraReDx's LipiScan IVUS Coronary Imaging System receives European CE Mark approval

InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced it has received CE Mark approval to begin commercialization of the LipiScan™ IVUS Coronary Imaging System throughout Europe.

20 Apr 2011

Florida Hospital uses flexible surgery instruments from Apollo Endosurgery for stomach tumor extraction

Florida Hospital Celebration Health announced this week the use of a new class of flexible surgical instruments created by Apollo Endosurgery®, to remove a stomach tumor and extract it through the patient's mouth. Following the two-hour surgery, the patient spent one night in the hospital and was prescribed Acetaminophen for pain.

20 Apr 2011

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative mitochondrial therapies, introduced its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion, during multiple scientific sessions of the Experimental Biology 2011 meeting.

20 Apr 2011

Treatment for Bipolar Disorder now available in Nova Scotia Formulary

The Nova Scotia Department of Health and Wellness has approved the listing of LITHMAX (Lithium Carbonate Sustained-Release 300mg Tablets) in the Nova Scotia Formulary, effective April 19th, 2011. This announcement comes as welcome news to patients in need of the sustained-release formulation of Lithium Carbonate who require help to pay for prescribed medications.

20 Apr 2011

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute for Cancer Research demonstrated the ability of GM-CT-01 (DAVANAT®) to enhance the ability of tumor-specific T-lymphocytes to kill tumor cells.

20 Apr 2011

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD Pharmaceuticals, Inc. today announced execution of three exclusive out-license agreements for separate aspects of its ARGENT™ cell-signaling regulation technology.

20 Apr 2011

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Oncolytics Biotech Inc. today announced interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases. The principal investigator of the study was Professor Alan Melcher of Leeds Institute of Molecular Medicine, University of Leeds, UK.

20 Apr 2011

PCRF awards $1.15 million grant to Children's Hospital Los Angeles

The Pediatric Cancer Research Foundation (PCRF) has awarded a five-year, $1.15 million grant to support the Clinical Trials Program in the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles.

20 Apr 2011

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Two new studies highlight the power of sequencing cancer patients' genomes as a diagnostic tool, helping doctors decide the best course of treatment and researchers identify new cancer susceptibility mutations that can be passed from parent to child.

20 Apr 2011

Blocking abnormal movement of mutated human FUS gene also blocks ALS process

In the first animal model of Amyotrophic Lateral Sclerosis (ALS), developed by Dr. Udai Pandey, Assistant Professor of Genetics at LSU Health Sciences Center New Orleans, Dr. Pandey's lab has found in fruit flies that blocking the abnormal movement of a protein made by a mutated gene called FUS also blocks the disease process.

20 Apr 2011

LMP1 viral protein needs TRAF6 cellular protein to promote B cell activation signaling pathways: Study

By identifying a surprising association of two intracellular proteins, University of Iowa researchers have laid the groundwork for the development of new therapies to treat B cell lymphomas and autoimmune disease.

20 Apr 2011

Adeona, TG United enter commercial-scale manufacturing agreement for reaZin

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement with TG United, Inc. of Brooksville, Florida, to provide commercial-scale manufacturing capabilities for reaZin. Adeona is developing reaZin, its product candidate for the dietary management of Alzheimer's disease and mild cognitive impairment, as a prescription medical food.

20 Apr 2011

KCMC uses Toshiba's diagnostic imaging systems to treat pediatric patients

As one of the leading pediatric centers in the United States, Kosair Children's Medical Center (KCMC) treats pediatric patients with conditions ranging from congenital heart disease to abdominal pain, to emergency trauma to juvenile diabetes and pediatric cancer.

20 Apr 2011

New state of myosin in cardiac muscle with low ATP turnover rate could decrease metabolic load of myocardium

New insight into the physiology of cardiac muscle may lead to the development of therapeutic strategies that exploit an inherent protective state of the heart. The research, published by Cell Press online on April 19th in the Biophysical Journal, discovers a state of cardiac muscle that exhibits a low metabolic rate and may help to regulate energy use and promote efficiency in this hard-working and vital organ.

20 Apr 2011

Whole-genome sequencing could soon improve cancer survival rates

Cancer survival rates could improve soon with whole-genome sequencing, according to two studies published in the April 20, 2011, issue of the Journal of the American Medical Association that describe the first clinical applications of the high-tech process in patients with cancer.

20 Apr 2011

Researchers discover new way to force cancer cells to self-destruct

Researchers at The Wistar Institute have found a new way to force cancer cells to self-destruct. Low doses of one anti-cancer drug currently in development, called Gamitrinib, sensitize tumor cells to a second drug, called TRAIL, also currently in clinical development as part of an anticancer regimen.

20 Apr 2011

Forest acquires worldwide rights to novel antiarrhythmic agent azimilide

Forest Laboratories, Inc. today announced that its wholly-owned subsidiary Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC have entered into an asset purchase agreement, pursuant to which Forest has acquired worldwide rights to azimilide, a novel antiarrhythmic agent originally developed by Procter & Gamble Pharmaceuticals.

20 Apr 2011

Minimizing neurological side effects in high-grade glioma patients may improve survival

Minimizing neurological side effects in patients with high-grade glioma from chemoradiation may result in improved patient survival, a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests. These findings were reported in the April issue of the British Journal of Cancer.

20 Apr 2011

Medical Condition News

FDA approves St. Jude Medical's Trifecta valve for stented aortic valve replacement

Brain trauma helped by nutrition

InfraReDx's LipiScan IVUS Coronary Imaging System receives European CE Mark approval

Florida Hospital uses flexible surgery instruments from Apollo Endosurgery for stomach tumor extraction

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Treatment for Bipolar Disorder now available in Nova Scotia Formulary

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

PCRF awards $1.15 million grant to Children's Hospital Los Angeles

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Blocking abnormal movement of mutated human FUS gene also blocks ALS process

LMP1 viral protein needs TRAF6 cellular protein to promote B cell activation signaling pathways: Study

Adeona, TG United enter commercial-scale manufacturing agreement for reaZin

KCMC uses Toshiba's diagnostic imaging systems to treat pediatric patients

New state of myosin in cardiac muscle with low ATP turnover rate could decrease metabolic load of myocardium

Whole-genome sequencing could soon improve cancer survival rates

Researchers discover new way to force cancer cells to self-destruct

Forest acquires worldwide rights to novel antiarrhythmic agent azimilide

Minimizing neurological side effects in high-grade glioma patients may improve survival

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Latest News